Pharma: Other News To Note
• Forest Laboratories Inc., of New York, said it received European approval to market Colobreathe (dry powder colistimethate sodium for inhalation) for treating cystic fibrosis patients, ages 6 and older, with chronic lung infections caused by P. aeruginosa.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.